

**PRESS RELEASE**

**VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY**

**In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)**

**Commenté [FC1]:** Attention, cette référence n'est à maintenir que pour la déclaration à faire dans les 15 jours suivant l'AG, pas pour les autres déclarations mensuelles.

**Paris, France, September 8, 2022**

Market: Euronext Paris / Nasdaq  
Euronext Compartment: B  
ISIN code: FR0011341205  
Nasdaq: NBTX  
Bloomberg: NANO:FP  
Reuters: NANO.PA  
Website: [www.nanobiotix.com](http://www.nanobiotix.com)

Date	Number of Shares Outstanding	Total number of voting rights	
		Total voting rights, theoretical <sup>(1)</sup>	Total voting rights, exercisable <sup>(2)</sup>
August 31, 2022	34,875,872	36,274,272	36,250,130

<sup>(1)</sup> The total number of theoretical (or "gross") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

<sup>(2)</sup> The total number of exercisable at a Shareholders' Meeting (or "net") voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

\*\*\*

**About NANOBIOTIX**

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at [www.nanobiotix.com](http://www.nanobiotix.com) or follow us on [LinkedIn](#) and [Twitter](#).

**Contacts**

---

*Nanobiotix*

---

**Nanobiotix Communications**

*Brandon Owens*  
VP, Communications  
+1 (617) 852-4835  
[contact@nanobiotix.com](mailto:contact@nanobiotix.com)

**Nanobiotix Investor Relations**

*Kate McNeil*  
SVP, Investor Relations  
+1 (609) 678-7388  
[investors@nanobiotix.com](mailto:investors@nanobiotix.com)

---

*Media Relations*

---

**France – Ulysse Communication**

*Pierre-Louis Germain*  
+ 33 (0) 6 64 79 97 51  
[plgermain@ulyse-communication.com](mailto:plgermain@ulyse-communication.com)

**LifeSci Advisors**

*Ligia Vela-Reid*  
+44 (0) 7413825310  
[lvela-reid@lifesciadvisors.com](mailto:lvela-reid@lifesciadvisors.com)

**NBTX**  
Nasdaq Listed

**NANO**  
LISTED  
EURONEXT